Hyperhomocysteinemia as a Predictive Factor for Inadequate Metabolic Control in Patients with Type II Diabetes Mellitus
Keywords:
descriptores volumétricos; ventrículos cerebrales; deterioro cognitivo leveAbstract
Introduction: Elevated blood homocysteine levels constitute a consequential risk factor for cardiovascular disease and are part of the complications in diabetic patients with metabolic dyscontrol.
Objective: To determine the predictive magnitude of hyperhomocysteinemia in the emergence of metabolic dyscontrol in patients with type II diabetes mellitus.
Methods: An observational and analytical study was conducted in 100 patients who attended the endocrinology service at the Provincial Center for Diabetic Care in Santiago de Cuba from September 2015 to January 2017, with an equal number of controls. The variables analyzed were: age, sex, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, homocysteine, and metabolic control. Descriptive statistics were used for demographic variables, and the mean and standard deviation were estimated for biochemical variables. Student's t-test was applied to compare the means of the determinations.
Results: It was evidenced that 8 out of every 10 diabetics with high homocysteine levels had metabolic dyscontrol, and that the cause of the imbalance among them was hyperhomocysteinemia, which was feasible for its use.
Conclusions: According to the results of this study, homocysteine should be analyzed in depth as a potential marker of metabolic control in type II diabetes mellitus.
Downloads
References
1.Valdés Hernández S, Alonso Gallardo SP. Diabetes mellitus tipo 2. Epidemiología y patogenia. Información para pacientes. SEEN. 2024 [citado 20/12/2025 ]:1-2. Disponible en: https://www.seen.es/documentos/pacientes-dm2-epidemiologia-patogenia
2.Organización Panamericana de la Salud. Washington: OPS; © 2024 [citado 25/02/2025]. Diabetes. Disponible en: https://www.paho.org/es/temas/diabetes
3.Sánchez Delgado JA, Sánchez Lara NE. Epidemiología de la diabetes mellitus tipo 2 y sus complicaciones. Rev. Finlay. 2022 [citado 20/12/2024]; 12(2):168-76. Disponible en: http://scielo.sld.cu/pdf/rf/v12n2/2221-2434-rf-12-02-168.pdf
4.Infomed Santiago. Santiago: Centro Provincial de Información de Ciencias Médicas; © 2008 – 2026 [actualización 19/12/2024; citado 20/12/2024]. Instan a incrementar diagnóstico de diabetes en Santiago de Cuba; [aprox. 1 pantalla]. Disponible en: https://www.infomed.scu.sld.cu/instan-a-incrementar-diagnostico-de-diabetes-en-santiago-de-cuba/
5.Denis de Armas R, Torres Yribar W, Cepero Llauger K, Alonso Rodríguez CA. La hiperhomocisteinemia como factor de riesgo en las enfermedades vasculares obstructivas. Rev Cubana Med. 2024 [citado 20/12/ 2024]; 63:e3373. Disponible en: http://scielo.sld.cu/pdf/med/v63/1561-302X-med-63-e3373.pdf
6.González Lamuño D, Arrieta Blanco FJ, Fuentes ED, Forga Visa MT, Morale -Conejo M, Peña Quintana L, et al. Hyperhomocysteinemia in adult patients: a treatable metabolic condition. Nutrients. 2023[citado 20/12/ 2024]; 16(1):135. Disponible en: https://doi.org/10.3390/nu16010135
7.American Diabetes Association Professional Practice Committee; Introduction and Methodology: Standards of Care in Diabetes—2025. Diabetes Care. 2025[citado 25/02/ 2025];48(Supplement_1):S1–S5.Disponible en: https://doi.org/10.2337/dc25-SINT
8.American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024. Diabetes Care. 2024[citado 25/02/ 2025];47(Supplement_1):S282–S294. Disponibe en: https://doi.org/10.2337/dc24-S015
9.Yuan D, Chu J, Lin H, Zhu G, Qian J, Yu Y, et al. Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis. Front Cardiovasc Med. 2023[citado 25/02/ 2025];9:1109445. Disponible en: https://doi.org/10.3389/fcvm.2022.1109445
10.Hormaza Ángel MP, Jaramillo Jaramillo LI, Londoño Isabel. Endocrinología ginecológica: claves para la práctica en la actualidad. 1ª ed. Medellín: Escuela Ciencias de la Salud; 2024[citado 24/12/2024]. 317 p. Disponible en: https://investigacion.upb.edu.co/ws/portalfiles/portal/70608947/LIBRO_Endocrinologia_ginecologica.pdf
11.Mora López IT, Parlá Sardiñas J. Parámetros para el control metabólico del diabético tipo 2. Rev Méd Electrón. 2024[citado 20/12/2024];46:e5619. Disponible en: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/5619/pdf 12.Soriguer F, Goday A, Bosch Comas A, Bordiú E, Calle Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetología. 2012[citado 25/02/ 2025];55(1):88-93. Disponible en: https://link.springer.com/article/10.1007/s00125-011-2336-9
13.Santos RD, Pereira C, Cesena F, Laurinavicius AG, Tabone V, Bittencourt MS. Cardiovascular Risk Misperception and Low Awareness of Familial Hypercholesterolemia in Individuals with Severe Hypercholesterolemia. Arq Bras Cardiol. 2021[citado 25/02/ 2025];116(4):706-12. Disponible en: https://www.scielo.br/j/abc/a/jszJ6cvvvN4HW38NSvGqhYH/?lang=en
14.Higuita García VA. Relación entre homocisteína, control metabólico y vitamina B12 en pacientes del programa prevención complicaciones de la diabetes, 2016 [tesis]. Bogotá: Universidad Nacional de Colombia. 2016 [citado 24/02/2024]. 90 p. Disponible en: https://repositorio.unal.edu.co/items/3b9ac243-32c6-4c35-baed-afc578f50455
15.Arrieta F, Botet JP, Tébard FJ, Ortega E, Nubiola A, Pardo JL, et al. Diabetes mellitus y riesgo cardiovascular: recomendaciones del Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2015). Atenc Primaria. 2021[citado 25/02/ 2025];48(5):325-36. Disponible en: https://www.sediabetes.org/wp-content/uploads/Diabetes-mellitus-y-riesgo-cardiovascular_actualizacion-recomendaciones-grupo-de-trabajo.pdf
16.Gallego Galano JM, Montoya Pedrón A, Rodríguez Estenger M, Álvarez Vicario R, Benítez Casamayor YB. Evaluación clínico vascular a pacientes diabéticos tipo 2 según niveles de homocisteína. Multimed. 2024 [citado 25/02/ 2025];28:e3044. Disponible en: http://scielo.sld.cu/pdf/mmed/v28/1028-4818-mmed-28-e3044.pdf
17.Quintana I, Genoud V. Implicancias fisiopatológicas de la hiperhomocisteinemia. Acta Bioquímica Clínica Latinoamericana. 2023[citado 25/02/ 2025];1(57):35-47. Disponible en: https://www.redalyc.org/journal/535/53575343005/html/
18.Rodríguez AC, Gomes GR, Oliveira MA. Associação entre hiperhomocisteinemia, polimorfismo C677T do gene MTHFR e risco cardiovascular. Brazilian Journal of Health Review. 2024[citado 25/02/ 2025];7(10):01-03. Disponible en: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/75323/52493
19.Núñez Cortes JM, Brea A, Díaz Rodríguez A, González Santos P, Hernández Mijares A, Mantilla T, et al. Dislipemias: de la fisiopatología al manejo clínico de las dislipemias aterogénicas. Clin Invest Hot Topics. 2013[citado 25/02/ 2025];6(2):13-9. Disponible en: https://www.researchgate.net/publication/262935469_Dislipemias_de_la_fisiopatologia_al_manejo_clinico_de_la_dislipemia_aterogenica
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 MEDISAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
